AgingResearch.NewsJoin free

Phase 3Completed

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine With a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older.

Sponsor
Merck Sharp & Dohme LLC (Industry)
Enrollment
850 enrolled
Conditions
Pneumococcal Infection
Interventions
V110; V114; mRNA-1273; Placebo for V110; Placebo for V114
Ages
adults, older adults
Registry
NCT05158140

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), with a 23-valent pneumococcal polysaccharide vaccine (V110) for the prevention of pneumococcal disease, or a 15-valent pneumococcal conjugate vaccine (V114) indicated for the prevention of invasive pneumococcal disease.

Primary outcomes

  • Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) Among Participants Administered V110
  • Percentage of Participants With Solicited Injection-Site Adverse Events Among Participants Administered V114
  • Percentage of Participants With Solicited Systemic AEs Among Participants Administered V110
  • Percentage of Participants With Solicited Systemic AEs Among Participants Administered V114

History

  1. Last registry update

  2. Results first posted

  3. Primary completion

  4. Started

  5. Registered

Papers citing this trial